Key Points
- Insider purchase: Jeffrey Yu bought 903,614 shares on April 1 at $0.83 each for a total of $749,999.62, raising his direct stake to 8,229,837 shares—about a 12.33% increase in his ownership.
- Company financials and stock: OneMedNet (NASDAQ:ONMD) trades near $1.10 with a market cap of ~$57.4M, reported quarterly EPS of $(0.07) on $0.89M revenue, and a 12‑month range of $0.31–$4.22.
- Market sentiment and ownership: The stock carries a consensus "Sell" rating (Weiss Ratings "sell (d-)"), institutional ownership is low at roughly 0.95%, though firms like State Street, Jane Street and Virtu recently built small positions.
OneMedNet Corporation (NASDAQ:ONMD - Get Free Report) Director Thomas Kosasa acquired 280,898 shares of the stock in a transaction that occurred on Thursday, April 23rd. The stock was acquired at an average cost of $0.89 per share, with a total value of $249,999.22. Following the completion of the purchase, the director owned 16,661,327 shares of the company's stock, valued at $14,828,581.03. This trade represents a 1.71% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Thomas Kosasa also recently made the following trade(s):
- On Friday, February 6th, Thomas Kosasa bought 595,238 shares of OneMedNet stock. The shares were acquired at an average cost of $0.84 per share, for a total transaction of $499,999.92.
OneMedNet Stock Performance
NASDAQ:ONMD opened at $1.10 on Friday. OneMedNet Corporation has a one year low of $0.31 and a one year high of $4.22. The firm has a market cap of $57.42 million, a P/E ratio of -15.71 and a beta of 1.16. The firm has a 50-day simple moving average of $0.80 and a 200-day simple moving average of $1.25.
OneMedNet (NASDAQ:ONMD - Get Free Report) last announced its quarterly earnings results on Monday, March 30th. The company reported ($0.07) earnings per share for the quarter. The firm had revenue of $0.89 million for the quarter.
Hedge Funds Weigh In On OneMedNet
A number of large investors have recently added to or reduced their stakes in ONMD. Virtu Financial LLC purchased a new stake in shares of OneMedNet during the fourth quarter valued at about $48,000. State Street Corp grew its position in shares of OneMedNet by 41.5% in the 4th quarter. State Street Corp now owns 116,700 shares of the company's stock worth $128,000 after buying an additional 34,200 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of OneMedNet in the 4th quarter worth approximately $119,000. HRT Financial LP bought a new position in shares of OneMedNet during the 4th quarter worth approximately $32,000. Finally, Exencial Wealth Advisors LLC raised its stake in shares of OneMedNet by 1.3% during the 4th quarter. Exencial Wealth Advisors LLC now owns 3,644,861 shares of the company's stock worth $4,009,000 after acquiring an additional 45,401 shares in the last quarter. 0.95% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of OneMedNet in a research report on Friday, January 9th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of "Sell".
Check Out Our Latest Analysis on OneMedNet
OneMedNet Company Profile
(
Get Free Report)
OneMedNet Corporation provides clinical imaging solutions. It offers iRWD, a solution that utilizes AI to securely de-identify, search, and curate imaging data for its partner network consisting of medical and academic research institutions to generate progression in stages of medical research, discovery and diagnostics that span the field of life sciences. OneMedNet Corporation is based in Eden Prairie, Minnesota.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
